▶주메뉴 바로가기
▶본문 바로가기
South Korean bio company OliPass is preparing to go public by the end of the year, according to sources on April 23. Preparing to start the initial public offering process, the company has picked Mi...
South Korean bio startup MitoImmune Therapeutics announced on April 22 that it has closed its series A round after raising 12 billion won ($10.5 million). Four investors -- the state-run Korea Devel...
Kyung Nam Pharm , a local drug maker known for its vitamin supplement Lemona, has decided to receive letters of intent from April 22-24 to find a new owner. The company plans to pick a buyer for it...
South Korean bio startup GenBody, which originally was planning an initial public offering this year, has changed its schedule, according to industry sources on April 18. According to sources, the f...
SK Biopharmaceuticals, a drug development unit of South Korea’s telecom-to-energy conglomerate SK Group , announced on April 18 that it has signed a contract with US-based biotech company twoXAR to...
Attempts to open a for-profit hospital in South Korea have collapsed, portending a long-drawn legal battle between Jeju Self-Governing Province and a Chinese group that feels betrayed. The approval ...
Korea Health Industry Development Institute announced on April 17 that it is hosting the Bio Korea International Convention from April 17-19. Session coordinators, including Bridge Bio CEO Lee Jung-...
NeoImmuneTech, an immunotherapy drug development company, announced on April 16 that its drug candidate HyLeukin-7 has been designated an orphan drug by the US Food and Drug Administration. HyLeukin...
Celltrion announced on April 11 that it has obtained marketing authorization from Health Canada for Truxima, its biosimilar for treating non-Hodgkin’s lymphoma. Truxima references Roche’s Rituxan (...
The share price of beleaguered Kolon Group ’s bio affiliates fluctuated after it announced its decision to suspend sales of Kolon Life Science’s new osteoarthritis drug Invossa on April 1 following...
An affiliate of South Korean biopharmaceutical firm Celltrion said Wednesday that the market share of its biosimilar Herzuma reached 10 percent in Europe during the fourth quarter of last year. C...
Korean health care startup Sky Labs aims to launch its Cardio Tracker, or CART, a ring-type wearable device that detects a patient’s heart rhythm 24/7 using internet of things technologies. “From th...
SK Biopharmaceuticals, the new drug development unit of South Korea’s telecom-to-energy conglomerate SK Group , is gearing up to go public on the main bourse Kospi. According to industry sources, ...
GC Pharma announced on April 4 that it has signed a deal with Clinigen KK in Japan to license out its Hunter syndrome treatment Hunterase ICV. Hunter syndrome is a rare genetic disorder that interfe...
Kolon Life Science announced on April 1 that it has decided to suspend sales of its new osteoarthritis drug Invossa. According to the company, the decision was made after the its US unit Kolon Tiss...
SK sets up hydrogen business group
Naver Cloud, GS Global join hands for overseas market
S. Korea invests $9.8m in World Bank green trust fund
Korean Air to sell Incheon yacht marina
Apple to make harder push in Korea with 2nd Apple Store
Warren Buffett’s favorite market indicator suggests Kospi may be overvalued
Federation of Korean banks appoints NH Financial chief as new head
News of potential deal with Tesla boosts Doosan Solus stocks
December 05, 2020
![[INTERVIEW] Sky Labs aims to launch CART in Europe this year](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=155&simg=/content/image/2019/04/09/20190409000869_p.jpg)
